maybe seeking a fight

Chemgenex’s extensive and detailed marketing of Ceflatonin over a long period has released a lot of knowledge, and fostered competitor action. See for example

http://cmlhope.com/?q=node/173


The Chemgenex board includes two corporate lawyers, a former practicing lawyer, a legal degree holder, and an MD of a co. with a history of corporate litigation. Its an OK bet they are shopping for a fight in respect of Ceflatonin’s patent protection.

CXS has three issued patents protecting the use of Ceflatonine’s active agent homoharringtonine (HHT), while nine others have been filed.

A derivative of the drug, Myelostat, is marketed by CXS partner Stragen Pharma. Stragen claims ownership to the complex process that underlies the production of HHT.

http://www.myelostat.com/myelostat.php